Comparative Pharmacology
Head-to-head clinical analysis: PREFEST versus SAFYRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREFEST versus SAFYRAL.
PREFEST vs SAFYRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREFEST combines estradiol (an estrogen) and norgestimate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), leading to gene transcription regulation, which promotes proliferation of endometrial tissue and secondary sexual characteristics. Norgestimate, a progestin, suppresses gonadotropin secretion and inhibits ovulation, and also counteracts estrogen-induced endometrial hyperplasia by inducing secretory transformation and reducing mitotic activity.
Safyral is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, preventing ovulation. Drospirenone is a progestin with anti-mineralocorticoid activity, which may reduce fluid retention, and anti-androgenic activity, which may improve acne. It also increases cervical mucus viscosity, impeding sperm penetration.
One tablet (estradiol 2 mg) orally once daily on days 1–3, then one tablet (estradiol 2 mg/norgestimate 0.09 mg) orally once daily on days 4–6; repeat cycle continuously.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.03 mg) orally once daily for 24 days, followed by 4 days of placebo.
None Documented
None Documented
Estradiol: 13-16 hours (terminal); estradiol valerate: 12-14 hours (prodrug hydrolysis rate-limiting); clinical context: once-daily dosing achieves steady-state in 5-7 days
16.3 hours (range 12-21 hours) for drospirenone; 32.5 hours (range 24-42 hours) for ethinyl estradiol (EE); clinical context: steady-state achieved after 10 days for drospirenone, 7 days for EE
Renal: 50-60% as glucuronide conjugates; fecal: 5-10% as unconjugated metabolites; biliary: minor (<5%)
Urine (40% as metabolites, 20% unchanged; fecal 30% as metabolites; biliary excretion contributes to enterohepatic circulation, prolonging elimination)
Category C
Category C
Estrogen/Progestin Combination Hormone Therapy
Oral Contraceptive Progestin/Estrogen